跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
PCSK9 GENE EDITING
首页
药物
PCSK9 GENE EDITING
PCSK9 GENE EDITING
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
PCSK9 endonuclease variants, compositions, and methods of use
US 11779654 B2
申请人: 2SEVENTY BIO INC
优先权: 2017
US
WO
5 件公开
GENE EDITING OF PCSK9
EP 3559223 A1
申请人: HARVARD COLLEGE
优先权: 2016
CN
EP
US
WO
4 件公开
COMPOSITIONS AND METHODS FOR TREATMENT OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9)-RELATED DISORDERS
EP 3585894 A1
申请人: CRISPR THERAPEUTICS AG
优先权: 2017
CN
EP
US
WO
4 件公开
COMPOSITIONS AND METHODS FOR IN VIVO NUCLEASE-MEDIATED GENE TARGETING FOR THE TREATMENT OF GENETIC DISORDERS
EP 4330412 A4
申请人: UNIV PENNSYLVANIA
优先权: 2021
EP
US
WO
3 件公开
GENE EDITING OF PCSK9 OR ANGPTL3 AND COMPOSITIONS AND METHODS OF USING SAME FOR TREATMENT OF DISEASE
EP 4405470 A4
申请人: VERVE THERAPEUTICS INC
优先权: 2021
EP
US
WO
3 件公开
METHODS FOR TREATMENT OF ORNITHINE TRANSCARBAMYLASE (OTC) DEFICIENCY
EP 4466367 A1
申请人: UNIV PENNSYLVANIA
优先权: 2022
EP
US
WO
3 件公开
COMPOSITIONS AND METHODS FOR IN VIVO NUCLEASE-MEDIATED GENE TARGETING FOR THE TREATMENT OF GENETIC DISORDERS IN ADULT PATIENTS
EP 4555087 A2
申请人: UNIV PENNSYLVANIA
优先权: 2022
EP
US
WO
3 件公开
COMPOSITION FOR PCSK9 GENE MODIFICATION OR EDITING, AND METHOD FOR USING SAME
WO 2025180418 A1
申请人: YOLTECH THERAPEUTICS CO LTD
优先权: 2024
CN
WO
2 件公开
METHOD FOR TARGETED REGULATION OF PCSK9 BY MEANS OF EPIGENETIC EDITING AND USE THEREOF
WO 2025261493 A1
申请人: EPIGENIC THERAPEUTICS INC
优先权: 2024
CN
WO
2 件公开
METHOD FOR PREPARING ENHANCED CAR-T-CELLS BASED ON INTERFERING OR KNOCKING OUT HUMAN PCSK9 GENE AND APPLICATION THEREOF
US 20260028585 A1
申请人: UNIV SHENZHEN
优先权: 2024
CN
US
2 件公开
第 1 / 2 页
上一页
下一页
药物
反馈